US Patent

US12076319 — Therapeutic regimens for treatment of paroxysmal nocturnal hemoglobinuria

Method of Use · Assigned to Achillion Pharmaceuticals Inc · Expires 2038-08-02 · 12y remaining

Vulnerability score 75/100 Vulnerable — likely target for IPR or design-around

What this patent protects

This patent protects methods for treating paroxysmal nocturnal hemoglobinuria by combining certain inhibitors with small molecule complement factor D inhibitors.

USPTO Abstract

Provided herein are methods for treating a subject with PNH comprising administering to a subject a therapeutically effective amount of complement component C5 (C5) inhibitor, complement component C3 (C3) inhibitor, or complement factor B (CFB) inhibitor in combination with a therapeutically effective amount of small molecule complement factor D (CFD) inhibitor of Formula I or Formula II, or a pharmaceutically acceptable salt thereof.

Drugs covered by this patent

danicopan (DANICOPAN)

FDA Patent Use Codes

When a patent is method-of-use, FDA lists it once per applicable indication ("U-code"). Each U-code carves out a specific therapeutic use that generic filers must either license or design around.

Code	Description	Drug
`U-3933`	—	danicopan
`U-3933`	—	danicopan

Patent Metadata

Patent number: US12076319
Jurisdiction: US
Classification: Method of Use
Expires: 2038-08-02
Drug substance claim: No
Drug product claim: No
Assignee: Achillion Pharmaceuticals Inc
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.